$IPHA

This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Innate Pharma (NASDAQ:IPHA), AeroVironment (NASDAQ:AVAV)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Innate Pharma S.A.

Original reporting
Benzinga · Avi Kapoor
Published Sep 18, 2025, 2:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 18, 2025, 2:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Innate Pharma (NASDAQ:IPHA), AeroVironment (NASDAQ:AVAV) — source image
Decision brief

The 30-second read

$IPHABullishMed
01

Why it matters

While some stocks face downward pressure, others may remain resilient; overall market impact appears limited.

02

Market read

The news primarily impacts US-based companies in the life sciences and financial sectors, with limited broader market implications.

03

What to watch

Potential upcoming sector catalysts or macroeconomic data releases could override current sentiment signals.

Timing: short-term (next 1-2 trading sessions)

Background

Recent analyst downgrades reflect a cautious outlook on certain stocks, possibly due to sector-specific challenges or broader market concerns.

Company-level read

Ticker impact

$IPHABullishMedium confidence
Context

High relevance due to positive sentiment and direct mention in analyst downgrade context.

Expected impact

Potential short-term volatility; a slight downward correction may occur, but long-term trend remains intact.

Evidence & confidence

Despite positive sentiment, the downgrade could trigger short-term profit-taking. Technical levels should be monitored for support.

$PGRNeutralLow confidence
Context

Moderate relevance with neutral sentiment and less direct impact.

Expected impact

Likely stability with minor fluctuations; no major movement expected.

Evidence & confidence

Relevance score and sentiment indicate limited influence from recent news, suggesting traders should wait for clearer signals.

Market effects

Life Sciences and Financials sectors may experience slight volatility due to analyst sentiment shifts.

Limited regional impact; primarily affecting US-listed stocks.

Minimal; news pertains mainly to US markets and specific sectors.

Counterpoint

Some analysts may interpret the downgrade as a buying opportunity, especially if the fundamentals remain strong.

Key entities

  • Innate Pharma S.A.

    A biotechnology company focused on immuno-oncology therapies.

  • AeroVironment, Inc.

    A provider of unmanned aircraft systems and tactical missile systems.

  • Wells Fargo & Co.

    A major American bank and financial services company.

  • The Progressive Corporation

    An insurance company specializing in auto, home, and other insurance products.

Related articles

$PGRMed

State Farm Just Handed $5 Billion Back to Customers. Here’s What That Says About Where Car Insurance Profits Are Headed

State Farm will return $5B to auto policyholders via a one-time dividend and roll back rates in several states. Progressive (PGR) and Allstate (ALL) reported strong Q2 earnings with combined ratios below 87. PGR earned $3.31B net income, while ALL returned $3.5B to shareholders. State Farm's move reflects improved loss trends and surplus. PGR gained 7% more policies year over year.

$IPHAMed

Innate Pharma Secures €30M, Extends Cash Runway Into 2028

Innate Pharma (NASDAQ:IPHA) completed enrollment in the dose-escalation portion of its Phase I trial of IPH4502, enrolling 76 patients by July 21. The company expects 10 to 15 patients at go-forward doses across post-PADCEV urothelial cancer, head and neck cancer, and NSCLC, with dose-escalation data later in 2024. Innate also awaits primary-endpoint data from AstraZeneca’s PACIFIC-9 monalizumab study by year-end, after a €30M financing extending its cash runway into 2028.

$IPHAHighAI 9/10

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

Innate Pharma SA (Euronext Paris: IPH, Nasdaq: IPHA) priced a €30 million offering of 17,647,059 new ordinary shares at €1.70 each, raising expected gross proceeds of about €30 million and net proceeds of about €27.6 million after fees. Proceeds will fund IPH4502 clinical development, preclinical ADC candidates, and working capital. Closing expected Aug 18, 2026; cash runway through Q1 2028 with Sobi upfront payment.

$IPHAMedAI 8/10

Innate Pharma SA: Innate Pharma Announces Proposed Offering of Ordinary Shares

Innate Pharma SA (Euronext Paris: IPH, Nasdaq: IPHA) announced a proposed private placement offering of about €22.5 million of ordinary shares. Net proceeds will fund continued development of IPH4502, preclinical ADC candidates, and working capital. Cash runway is until end-Q3 2026, or Q3 2027 after a $75m Sobi upfront payment, subject to conditions.